Office of Technology Development

The Office of Technology Development manages Memorial Sloan Kettering’s world-class portfolio of intellectual property. We are responsible for:

• Identifying and evaluating new inventions
• Seeking patent protection
• Developing, managing, and commercializing the institution’s innovations
• Facilitating start-up creation.

The goal of our technology transfer activities is to ensure that scientific research at Memorial Sloan Kettering is developed and applied for the common good.

For legal support relating to intellectual property  and pre-clinical or clinical research agreements, contact a member of our Legal team.

• About Us
  The Office of Technology Development’s mission is to ensure that Memorial Sloan Kettering’s inventions have the greatest chance of benefiting patients.
• Our Staff
  The office is staffed by technology transfer professionals with backgrounds in science, intellectual property, and business development.
• Success Stories
  Research conducted at Memorial Sloan Kettering has produced ten drugs FDA approved for marketing, and one product approved by the USDA.
• Technologies Available for Licensing
  We offer opportunities for developing new devices, diagnostics, research tools, therapeutics, and vaccines.
• Digital Health Projects
  At MSK, we are leaders in the field of digital health. Our investigators, clinicians, and health technology professionals are working on a wide range of opportunities to bring the promise of our cutting-edge technologies, deep expertise in clinical validation, and portfolio of digital assets to our mission of improving the health care and quality of life of people with cancer.
• MSK Innovation Hub
  Learn about MSK Innovation Hub, an accelerator program designed to encourage collaborations between Memorial Sloan Kettering Cancer Center and digital health companies, focused on the diagnosis, treatment, and care of cancer patients.
• MSK Therapeutics Accelerator
  Learn about the MSK Therapeutics Accelerator, a business accelerator program launched by MSK in 2023. This selective partnership program fosters and accelerates innovative collaborations between MSK and biotech and pharmaceutical companies worldwide.
• OncoKB®
  
• Tangible Materials Available for Licensing
  We have an extensive collection of tangible research materials, including cell lines, antibodies, reagents, and mouse models, which are available for licensing on a non-exclusive basis for research and commercial purposes.
• Contact OTD
  Learn more about how to reach us by phone, e-mail, regular mail, or courier.